Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 5,000,000 target

The Pediatric Anesthesia Quality Improvement Project

The Society for Pediatric Anesthesia

NCT00674388

Recruiting 999,999 target

Molecular Genetics Studies of Cancer Patients and Their Relatives

City of Hope Medical Center

NCT04185935

Recruiting 500,000 target

Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies

Banner Health

NCT02022943

Recruiting 150,000 target

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

Children's Hospital of Philadelphia

NCT02493478

Recruiting 100,000 target

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00342927

Recruiting 100,000 target

US National OCS Heart Perfusion (OHP) Registry

TransMedics

NCT05915299

Recruiting 100,000 target

Product Surveillance Registry

Medtronic

NCT01524276

Recruiting 100,000 target

US National OCS Liver Perfusion (OLP) Registry

TransMedics

NCT05940857

Recruiting 100,000 target

Caris Biorepository Research Protocol

Caris Science

NCT01499394

Recruiting 100,000 target

Epilepsy Learning Healthcare System (ELHS)

Epilepsy Foundation of America

NCT06265103

Recruiting 99,999 target

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Center for International Blood and Marrow Transplant Research

NCT01351545

Recruiting 75,000 target

Project: Every Child for Younger Patients With Cancer

Children's Oncology Group

NCT02402244

Recruiting 50,000 target

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio

NCT03452774

Recruiting 40,000 target

Registry Study for Radiation Therapy Outcomes

Proton Collaborative Group

NCT01255748

Recruiting 35,000 target

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

CHDI Foundation

NCT01574053

Recruiting Phase 3 32,000 target

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

Pfizer

NCT07282665

Recruiting 30,000 target

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Mayo Clinic

NCT06271291

Recruiting 30,000 target

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Agendia

NCT03053193

Recruiting Phase 4 30,000 target

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

ModernaTX

NCT07266558

Recruiting 27,000 target

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy

Aventyn

NCT04678193

Recruiting Phase 3 25,500 target

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

BioNTech SE

NCT07300839

Recruiting 25,000 target

Parkinson's Foundation PD GENEration Genetic Registry

Parkinson's Foundation

NCT04994015

Recruiting Phase 4 20,000 target

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Duke University

NCT04262206

Recruiting 20,000 target

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Duke University

NCT02418442

Recruiting 20,000 target

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Medtronic

NCT00271180

Recruiting 20,000 target

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

Mayo Clinic

NCT00830557

Recruiting 20,000 target

Pancreatic Cancer Early Detection Consortium

Arbor Research Collaborative for Health

NCT04970056

Recruiting Phase 3 15,100 target

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

AstraZeneca

NCT07000357

Recruiting 15,000 target

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Target PharmaSolutions

NCT02815891

Recruiting 15,000 target

Patient Retrospective Outcomes (PRO)

Boston Scientific Corporation

NCT01550575

Recruiting 15,000 target

Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

Heart Rhythm Clinical and Research Solutions

NCT04088071

Recruiting Phase 3 15,000 target

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Janssen Research & Development

NCT05702034

Recruiting Phase 3 13,000 target

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Hoffmann-La Roche

NCT07177352

Recruiting Phase 3 12,800 target

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Amgen

NCT07037433

Recruiting 12,000 target

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Genzyme, a Sanofi Company

NCT00358943

Recruiting Phase 3 11,800 target

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Boehringer Ingelheim

NCT07064473

Recruiting Phase 3 11,300 target

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

AstraZeneca

NCT06677060

Recruiting Phase 3 11,000 target

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Alnylam Pharmaceuticals

NCT07181109

Recruiting Phase 3 11,000 target

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Amgen

NCT07136012

Recruiting Phase 3 11,000 target

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Boehringer Ingelheim

NCT06531824

Recruiting Phase 3 10,450 target

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Eli Lilly and Company

NCT07157774

Recruiting 10,000 target

Arizona Cancer Center Biospecimen Repository

University of Arizona

NCT00896935

Recruiting 10,000 target

Innovations in Genicular Outcomes Registry

Pacira Pharmaceuticals

NCT05495334

Recruiting Phase 2 10,000 target

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

SWOG Cancer Research Network

NCT03851445

Recruiting Phase 2 10,000 target

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Eli Lilly and Company

NCT05986292

Recruiting 10,000 target

US National TOP Registry

TransMedics

NCT06513091

Recruiting Phase 3 10,000 target

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Novo Nordisk A/S

NCT06118281

Recruiting Phase 2 9,999 target

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

New York Blood Center

NCT01656603

Recruiting NA 9,500 target

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

NRG Oncology

NCT05080673

Recruiting 9,000 target

Fabry Disease Registry & Pregnancy Sub-registry

Genzyme, a Sanofi Company

NCT00196742

Recruiting NA 8,946 target

Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

Dartmouth-Hitchcock Medical Center

NCT05612347

Recruiting Phase 4 8,600 target

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Currax Pharmaceuticals

NCT06098079

Recruiting 8,000 target

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

Massachusetts General Hospital

NCT04916210

Recruiting 8,000 target

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

Stryker Instruments

NCT03072927

Recruiting NA 7,500 target

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Cleerly

NCT06112418

Recruiting NA 7,500 target

Prospective Case Collection Study for New Mammography Technologies

Hologic

NCT05199701

Recruiting 7,500 target

MYLUNG Consortium Part 3: Observational Study

US Oncology Research

NCT05885698

Recruiting Phase 4 7,410 target

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

VA Office of Research and Development

NCT02915198

Recruiting Phase 3 6,700 target

Pediatric Dose Optimization for Seizures in Emergency Medical Services

Stanford University

NCT05121324

Recruiting 6,550 target

Non-Invasive Preeclampsia Screening and Biobank

Sequenom

NCT06643741

Recruiting NA 6,250 target

Platform of Randomized Adaptive Clinical Trials in Critical Illness

University Health Network, Toronto

NCT05440851

Recruiting Phase 3 6,000 target

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Pfizer

NCT07160244

Recruiting Phase 3 5,951 target

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

NCT03959085

Recruiting Phase 3 5,600 target

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Novo Nordisk A/S

NCT05636176

Recruiting Phase 3 5,500 target

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

AstraZeneca

NCT05952557

Recruiting 5,500 target

CCM OPEN HF Registry

Impulse Dynamics

NCT07112924

Recruiting Phase 3 5,350 target

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Johns Hopkins University

NCT05836987

Recruiting Phase 3 5,200 target

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Colorado Prevention Center

NCT06008197

Recruiting Phase 3 5,056 target

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Amgen

NCT07037459

Recruiting 5,000 target

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

University of Michigan

NCT06104969

Recruiting Phase 3 5,000 target

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

AstraZeneca

NCT06283966

Recruiting Phase 2 5,000 target

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

QuantumLeap Healthcare Collaborative

NCT01042379

Recruiting Phase 3 5,000 target

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

AstraZeneca

NCT06742723

Recruiting 5,000 target

Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

The University of Texas Health Science Center, Houston

NCT05685745

Recruiting 5,000 target

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

Boston Scientific Corporation

NCT03664609

Recruiting 5,000 target

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Children's Oncology Group

NCT00736749

Recruiting 5,000 target

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Duke University

NCT04278404

Recruiting 5,000 target

Vincere Biobank Research Protocol

Vincere Cancer Center

NCT05954299

Recruiting Phase 3 4,800 target

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

AstraZeneca

NCT06307652

Recruiting 4,800 target

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

Boston Scientific Corporation

NCT01719055

Recruiting NA 4,800 target

Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program

Arizona State University

NCT05485675

Recruiting Phase 3 4,500 target

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Eli Lilly and Company

NCT07165028

Recruiting 4,500 target

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Michael J. Fox Foundation for Parkinson's Research

NCT04477785

Recruiting 4,490 target

Observational Study Protocol: LIVER-R

AstraZeneca

NCT06252753

Recruiting 4,400 target

Blue Light Cystoscopy With Cysview® Registry

Photocure

NCT02660645

Recruiting Phase 3 4,300 target

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

AstraZeneca

NCT05774951

Recruiting Phase 2 4,292 target

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

BioNTech SE

NCT05543616

Recruiting Phase 3 4,220 target

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Stemline Therapeutics

NCT06492616

Recruiting Phase 2 4,200 target

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

American Society of Clinical Oncology

NCT02693535

Recruiting 4,000 target

EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

Natera

NCT06808880

Recruiting 4,000 target

American Lung Association (ALA) Lung Health Cohort

Johns Hopkins University

NCT04543461

Recruiting 4,000 target

Fecal Microbiota Transplant National Registry

American Gastroenterological Association

NCT03325855

Recruiting Phase 3 4,000 target

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Vaxcyte

NCT07284654

Recruiting NA 4,000 target

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

University of British Columbia

NCT04634240

Recruiting Phase 3 3,960 target

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NRG Oncology

NCT05879926

Recruiting Phase 3 3,680 target

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

NCT06058377

Recruiting 3,600 target

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

George Washington University

NCT06525259

Recruiting Phase 3 3,500 target

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Merck Sharp & Dohme

NCT03486873

Recruiting 3,500 target

Lupus Landmark Study: A Prospective Registry and Biorepository

Lupus Research Alliance

NCT05934149

Recruiting 3,375 target

Shield Post-Approval Study Protocol

Guardant Health

NCT06880055

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →